Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DVX201
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Coeptis Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Coeptis will get exclusive rights to two FDA approved IND applications and two phase 1 clinical trials investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies a...
Brand Name : DVX201
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : DVX201
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Coeptis Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?